Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Reports Millions In Unpaid GDUFA Fees

Agency figures reveal a shortfall of more than $20m last year

Executive Summary

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

You may also be interested in...



User Fee Delinquencies Rising At US FDA After PDUFA Redesign

Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.

Generic Companies Race To Withdraw ANDAs

Industry consolidation may be a reason ANDA withdrawals have increased during GDUFA II.

Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel